ISRCTN18435077 https://doi.org/10.1186/ISRCTN18435077

Realisation of established targets for patients with diabetes type 2 at primary care setting

Submission date
19/12/2005

Recruitment status
No longer recruiting

Registration date
19/12/2005

Overall study status
Completed

Last Edited
03/07/2008

Condition category
Nutritional, Metabolic, Endocrine

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[ ] Results
[ ] Individual participant data
[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr M.A. van de Ree

Contact details
Diakonessenhuis Utrecht/Zeist
P.O. Box 1002
Zeist
Netherlands
3700 BA
+31 (0)30 6989787
mvdree@diakhuis.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
NTR391

Study information

Scientific Title

Acronym
Feistritz-trial

Study objectives
Targets of blood pressure, glucose and cholesterol are more feasible with rosiglitazone and structured treatment advice.

Please note that as of 03/07/2008 more details on the sources of funding have been added to this record. This can be seen below in the sources of funding section.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethics approval received from the local medical ethics committee.

Study design
Multicentre, randomised, placebo controlled, parallel group trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Diabetes mellitus type II (DM type II)

Interventions
Two treatment arms:
Arm A: Addition of rosiglitazone 8 mg once daily (od) or
Arm B: No addition of rosiglitazone

For each patient a regimen of treatment will be arranged concerning the glucose, blood pressure and cholesterol targets.

Intervention Type

Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Rosiglitazone

Primary outcome measure
The total amount of targets reached with treatment with rosiglitazone compared with treatment with no rosiglitazone.

Secondary outcome measures
The outcome of glitazone on the recently discovered risk factors of diabetic patients.

Overall study start date
01/12/2003

Completion date
01/01/2010

Eligibility

Key inclusion criteria
1. Patients with type 2 diabetes
2. Signed informed consent

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
500

Key exclusion criteria
1. Aged less than 18 years
2. Quality-adjusted life years (QALY) less than 5 years
3. Use of insulin, fibrates or thiazolidines less than 6 weeks before inclusion
4. Heart failure, New York Heart Association (NYHA) class II or more
5. Myocardial infarction (MI), angina pectoris (AP), transient ischaemic attack (TIA) or cerebrovascular attack (CVA) less than 3 months before randomisation
6. Surgery, severe trauma or infection less than 3 months before randomisation
7. Known liver disease or alanine aminotransferase (ALT), aspartate aminotransferase (AST),

gamma glutamyltransferase (GT) greater than three times upper limit
8. Serum creatinine greater than 150 mmol/l
9. Triglycerides greater than 8 mmol/l

Date of first enrolment
01/12/2003

Date of final enrolment
01/01/2010

Locations

Countries of recruitment
Netherlands

Study participating centre
Diakonessenhuis Utrecht/Zeist
Zeist
Netherlands
3700 BA

Sponsor information

Organisation
Aventis (The Netherlands)

Sponsor details
Postbus 2043
Gouda
Netherlands
2800 BD
+31 (0)182 557696
info.nl@aventis.com

Sponsor type
Not defined

ROR
https://ror.org/00pgqb537

Funder(s)

Funder type

Industry

Funder Name
Added on 03/07/2008:

Funder Name
Grants from:

Funder Name
GlaxoSmithKline (The Netherlands)

Alternative Name(s)
GlaxoSmithKline plc., GSK plc., GSK

Funding Body Type
Government organisation

Funding Body Subtype
For-profit companies (industry)

Location
United Kingdom

Funder Name
Sanofi-Aventis (The Netherlands)

Funder Name
Merck Sharp and Dohme (The Netherlands)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration